Symbols

CRIS

Curis·NASDAQ

--(--)

CRIS fundamentals

CRIS Q4 2025 Earnings

Curis (CRIS) released its earnings on Mar 19, 2026: revenue was 1.14M (YoY -65.98%), missed estimates; EPS was 1.23 (YoY +198.40%), beat estimates.

Revenue / YoY

1.14M

-65.98%

EPS / YoY

1.23

+198.40%

Report date

Mar 19, 2026

CRIS Earnings Call Summary for Q4,2025

One-Time Financial Boost: Q4 2025 net income of $19.4M driven by a $27.2M gain from Erivedge sale, with no future revenue from the asset.
Top Priorities: PCNSL registrational study and CLL proof-of-concept trial take precedence over AML.
CLL Potential: Dual blockade of BCR and TLR pathways aims for complete remission in CLL, with initial data expected at ASH 2026.
AML Progress: Triplet therapy achieved MRD conversion in 5/8 patients, highlighting disease-modifying potential.

Earnings

EPS

Revenue

Revenue & Expenses

CRIS has released its 2025 Q4 earnings report, with revenue of 1.14M, reflecting a YoY change of -65.98%, and net profit of 19.36M, showing a YoY change of 301.25%. The Sankey diagram below clearly presents CRIS's revenue sources and cost distribution.

Key Indicators

Curis (CRIS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Curis (CRIS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Curis (CRIS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Curis (CRIS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown